CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increase potential applications in drug delivery
4.1.2. Emerging adoption of nanotechnology in the healthcare industry
4.1.3. Growing government initiatives and R&D in pharmaceuticals
4.1.4. Advancements in nanoparticle analysis technologies.
4.2. Market Restraints & Challenges
4.2.1. Huge expenses on product development and R&D
4.2.2. Stringent rules for developing enhanced medical products.
4.3. Market Opportunities
4.3.1. Emerging development of engineered Nano-materials tools for human healthcare
4.3.2. Technological advancements in emerging economies.
CHAPTER 5 GLOBAL NANOPARTICLES MARKET – BY TECHNOLOGY
5.1. Inorganic nanoparticles
5.1.1. Gold nanoparticles
5.1.2. Iron oxide magnetic nanoparticle
5.1.3. Others
5.2. Dendrimers
5.3. Polymer-conjugated drugs
5.4. Polymeric nanoparticles
5.5. Liposomes
5.6. Nanotubes
5.7. Others
CHAPTER 6 GLOBAL NANOPARTICLES MARKET – BY APPLICATION
6.1. Drug delivery
6.2. Drug development
6.3. Biotechnology
6.3.1. Biosensors
6.3.2. In vitro imaging
6.3.3. Stem cell research
6.3.4. Cellular repair
6.3.5. Research and development
6.4. Medical & dentistry
6.5 Electronics
6.6. Catalyst
6.7 Glass
6.8. Cosmetics
6.9. Others
CHAPTER 7 GLOBAL NANOPARTICLES MARKET – BY END USER
7.1. Diagnostic Centers
7.2. Ambulatory Surgery Centers
7.3. Hospitals
7.4. Research institutions
7.5. Biochemical Industry
7.6. Pharmaceuticals Industry
7.7. Others
CHAPTER 8 GLOBAL NANOPARTICLES MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9 GLOBAL NANOPARTICLES MARKET - COMPANY PROFILES
9.1. Abraxis Biosciences, Inc.
9.2. Novartis International AG
9.3. Gilead Sciences, Inc.
9.4. Johnson & Johnson Inc.
9.5. Sigma-Tau Pharmaceuticals, Inc.
9.6. Amgen, Inc.
9.7. Nano Interface Technology, Inc.
9.8. GE Healthcare
9.9. Horiba Ltd.
9.10. Beckman Coulter Inc.
9.11. Merck. Co, Inc.
9.12. Agilent Technology Inc.
9.13. Hitachi Ltd.
9.14. Wyatt Technology, Corporation
9.15. Nanostellar Inc.
CHAPTER 10 GLOBAL NANOPARTICLES MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11 MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12 APPENDIX
12.1. List of Tables
12.2. List of Figures
